These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 6411952

  • 1. [Excretion of 5-S-cysteinyldopa in the urine of Japanese patients with malignant melanoma--a helpful biochemical marker for assessing the progression of disease].
    Hanawa S.
    Nihon Hifuka Gakkai Zasshi; 1983 Mar; 93(4):433-42. PubMed ID: 6411952
    [No Abstract] [Full Text] [Related]

  • 2. Cysteinyldopa isomers and dopa in lesions and urine of Japanese patients with malignant melanoma.
    Morishima T, Tatsumi F, Fukada E, Saito M, Fujita M, Nagashima N, Hanawa S.
    Arch Dermatol Res; 1983 Mar; 275(2):76-9. PubMed ID: 6409012
    [Abstract] [Full Text] [Related]

  • 3. Urinary excretion of 5-S-cysteinyldopa in healthy Japanese.
    Morishima T, Hanawa S.
    Acta Derm Venereol; 1981 Mar; 61(2):149-50. PubMed ID: 6165192
    [Abstract] [Full Text] [Related]

  • 4. Urinary free and conjugated 5-S-cysteinyldopa in normal subjects and in patients with melanoma.
    Graef V, Paul E.
    Br J Dermatol; 1982 Jan; 106(1):53-7. PubMed ID: 6800394
    [Abstract] [Full Text] [Related]

  • 5. 5-S-cysteinyldopa in the urine of melanoma patients.
    Agrup G, Agrup P, Andersson T, Falck B, Hansson JA, Jacobsson S, Rorsman H, Rosengren E, Rosengren AM.
    Acta Derm Venereol; 1977 Jan; 57(2):113-6. PubMed ID: 71802
    [Abstract] [Full Text] [Related]

  • 6. [Comparative studies between excretion of 5-S-cysteinyldopa and indole melanogens in urine].
    Beyer C, Fiedler H, Wohlrab W, Wozniak KD.
    Dermatol Monatsschr; 1986 Jan; 172(9):541-4. PubMed ID: 3098590
    [No Abstract] [Full Text] [Related]

  • 7. 5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis.
    Agrup G, Agrup P, Andersson T, Hafström L, Hansson C, Jacobsson S, Jönsson PE, Rorsman H, Rosengren AM, Rosengren E.
    Acta Derm Venereol; 1979 Jan; 59(5):381-8. PubMed ID: 93360
    [Abstract] [Full Text] [Related]

  • 8. [5-S-cysteinyldopa in the urine - a "tumor test" for malignant melanoma? Comparison with the usual laboratory examinations].
    Paul E, Graef V, Ruppel R.
    Z Hautkr; 1980 Dec 01; 55(23):1543-60. PubMed ID: 6782780
    [Abstract] [Full Text] [Related]

  • 9. [5-S-cysteinyldopa determination in the urine. Its value for monitoring in melanoma patients].
    Paul E, Graef V, Ruppel R, Hellwich M.
    Z Hautkr; 1983 Feb 15; 58(4):262-5. PubMed ID: 6405551
    [Abstract] [Full Text] [Related]

  • 10. [Urinary 5-S-cysteinyldopa in malignant melanoma subjects-with special reference to melanoma stages and dopa loading test (author's transl)].
    Ichihasi M, Mojamdar M, Mishima Y.
    Nihon Hifuka Gakkai Zasshi; 1981 Sep 15; 91(10):1045-9. PubMed ID: 6798247
    [No Abstract] [Full Text] [Related]

  • 11. Isolation of 2-S-cysteinyldopa and 2,5-S,S-dicysteinyldopa from the urine of patients with melanoma.
    Prota G, Rorsman H, Rosengren AM, Rosengren E.
    Experientia; 1977 Jun 15; 33(6):720-1. PubMed ID: 891724
    [No Abstract] [Full Text] [Related]

  • 12. [Therapeutic evaluation of human malignant melanoma by urinary 5-S-cysteinyldopa dynamics: chemotherapy and surgery].
    Inoi T, Mojamdar M, Ichihashi M, Mishima Y.
    Nihon Hifuka Gakkai Zasshi; 1984 Jan 15; 94(1):39-43. PubMed ID: 6433083
    [No Abstract] [Full Text] [Related]

  • 13. Treatment of malignant melanoma with dacarbazin (DTIC-DOME) with special reference to urinary excretion of 5-S-cysteinyldopa.
    Jönsson PE, Agrup G, Arnbjörnsson E, Hafström L, Rorsman H.
    Cancer; 1980 Jan 15; 45(2):245-8. PubMed ID: 6153150
    [Abstract] [Full Text] [Related]

  • 14. Urinary 5-S-cysteinyldopa in Parkinsonism after DOPA and carbidopa.
    Stewart RM, Miller S, Gunder M.
    Acta Derm Venereol; 1983 Jan 15; 63(2):97-101. PubMed ID: 6189350
    [Abstract] [Full Text] [Related]

  • 15. The urinary melanogen cysteinyldopa in melanoma and in suntanning: Australian experience.
    Nixon PF.
    Aust N Z J Surg; 1978 Feb 15; 48(1):17-21. PubMed ID: 276342
    [Abstract] [Full Text] [Related]

  • 16. [Treatment of malignant melanoma with DTIC--therapeutic effects determined by 5-S-cysteinyldopa changes in the urine (proceedings)].
    Agrup G, Hafström L, Jönsson PE, Rorsman H.
    Lakartidningen; 1978 Dec 06; 75(49):4599-600. PubMed ID: 364213
    [No Abstract] [Full Text] [Related]

  • 17. Detection and quantitation of 5-S-cysteinyldopa in melanotic and amelanotic melanoma in comparison with nonpigment cell tumors and it's urinary excretion.
    Mojamdar M, Ichihashi M, Mishima Y.
    J Dermatol; 1979 Dec 06; 6(6):379-82. PubMed ID: 120380
    [No Abstract] [Full Text] [Related]

  • 18. Urine excretion of 5-S-cysteinyldopa and serum sialic acid as tumor markers in human melanomas.
    Marnot D, Decaux F, Berthelot P, Kalis B, Jardillier JC, Warren L.
    Cancer Detect Prev; 1983 Dec 06; 6(1-2):303-10. PubMed ID: 6411338
    [Abstract] [Full Text] [Related]

  • 19. Urinary excretion of melanocytic metabolites in fertile women.
    Carstam R, Hansson C, Rorsman H, Rosengren E, Sjöberg NO, Wirestrand LE.
    Acta Derm Venereol; 1985 Dec 06; 65(6):543-5. PubMed ID: 2420122
    [Abstract] [Full Text] [Related]

  • 20. 5-S-cysteinyldopa in diagnosis and treatment of human malignant melanomas and ultrastructural observations.
    Aubert C, Rosengren E, Rorsman H, Rouge F, Foa C, Lipcey C.
    Eur J Cancer (1965); 1977 Nov 06; 13(11):1299-308. PubMed ID: 590287
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.